glp 1 ibd More encouraging news about GLP-1 medications. New research presented at ASCO found that patients with inflammatory bowel disease (IBD) who used GLP- receptor agonists had a 51% lower odds of developing colorectal Ever wondered how obesity, IBD,

References (this section): NEJM (2023): Retatrutide Phase 2 trial in obesity (mechanism + outcomes context) Eli Lilly: Phase 2 retatrutide results published in NEJM Retatrutide clinical trials (TRIUMPH program): whats being studied Searches like retatrutide clinical trials and retatrutide trial sign up usually point to the sponsors Phase 3 program (often referred to as the TRIUMPH program) plus other listings in official registries

Improved Blood Pressure and Cholesterol Levels In addition to their effects on blood glucose and weight, GLP-1 receptor agonists also contribute to improvements in blood pressure and lipid profiles, which can further reduce the risk of cardiovascular disease. Standard GLP-1 Dosing: What's Established Typical Doses The prescribed doses of GLP-1 receptor agonists are based on extensive clinical research and established therapeutic guidelines

Bellward GD, Warren PM, Howald W, et al

Why do some research protocols report better outcomes with conservative tirzepatide dosing when stacking with 5-amino-1MQ